Relevant pharmacogenetic association studies that focused on cytochrome P450 (CYP)
| Study | Gene | Drug | Results | Quality (0–31) | Sample size |
|---|---|---|---|---|---|
| Zackrisson et al. (48) | CYP2D6 CYP2C19 | Various antidepressants | UM genotype ↑ suicide cases | 8 | 504 |
| Serretti et al. (49) | CYP1A2 CYP2C9 CYP2C19 CYP2D6 | Various antidepressants | No association between metabolic profiles and either response or remission rates | 13 | 278 |
| Peters et al. (50) | CYP2D6 CYP2C19 CYP3A4 CYP3A5 | Citalopram | No association with response or tolerance phenotypes | 25 | 1953 |
| David et al. (42) | CYP2B6 | Bupropion | DRD2 rs1800497 A2/A2 subject with rs3211371 T/T or C/T genotype ↑ abstinence | 15 | 233 |
| Shams et al. (51) | CYP2D6 | Venlafaxine | PM phenotype ↑ side effects | 11 | 25 |
| Yin et al. (40) | CYP2C19 | Citalopram | PM phenotype ↑ drug plasma concentrations and side effects | 15 | 53 |
| Suzuki et al. (52) | CYP2D6 | Fluvoxamine | CYP2D6 IM with 5-HT2A rs63311 G/G or A/G ↑↑ gastrointestinal side effects | 18 | 96 |
| Grasmader et al. (53) | CYP2C9 CYP2C19 CYP2D6 | Various | CYP2D6 ↑↑, CYP2C19 ↑, CYP2C9 – antidepressant plasma concentrations | 14 | 112 |
| Rau et al. (54) | CYP2D6 | Various | PM ↑ side effects | 5 | 28 |
| Charlier et al. (55) | CYP2D6 | Fluoxetine, paroxetine | PM ↑ plasma concentrations | 9 | 49 |
| Ohara et al. (56) | CYP2D6 | Fluvoxamine | No association with fluvoxamine concentration | 12 | 46 |
| Murphy et al. (57) | CYP2D6 | Paroxetine, mirtazapine | No association | 18 | 122 |
↑= positive association; ↓ = negative association; IM = intermediate metabolizer; PM = poor metabolizer; UM = ultrarapid metabolizer.